Ignite Creation Date:
2025-12-25 @ 1:17 AM
Ignite Modification Date:
2025-12-27 @ 2:07 AM
Study NCT ID:
NCT05432193
Status:
TERMINATED
Last Update Posted:
2025-06-25
First Post:
2022-06-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Sponsor:
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-13
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-10-02
Completion Date Type:
ACTUAL
First Submit Date:
2022-06-08
First Submit QC Date:
None
Study First Post Date:
2022-06-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-19
Last Update Post Date:
2025-06-25
Last Update Post Date Type:
ACTUAL